<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00130117</url>
  </required_header>
  <id_info>
    <org_study_id>2004P000123</org_study_id>
    <secondary_id>1R34HD048526-01</secondary_id>
    <secondary_id>5M01RR001032-32</secondary_id>
    <nct_id>NCT00130117</nct_id>
  </id_info>
  <brief_title>Study of Leptin for the Treatment of Hypothalamic Amenorrhea</brief_title>
  <official_title>Randomized, Double-blind, Placebo-controlled Trial of Human Recombinant Leptin (r-metHuLeptin) for the Treatment of Hypothalamic (Exercise-Induced) Amenorrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether administration of an investigational
      medication called leptin (r-metHuLeptin) in replacement doses can improve bone health,
      reproductive function, hormone levels, immune function, and overall sense of well-being in
      women with hypothalamic (exercise-induced) amenorrhea (HA) who are being treated with oral
      contraceptive pills (OCPs), compared to placebo. Women with hypothalamic amenorrhea have low
      leptin levels. This study is based on the hypothesis that the relative leptin deficiency in
      women with hypothalamic (exercise-induced) amenorrhea may be the reason for the lack of
      menstrual cycles, hormone abnormalities, and bone loss associated with this condition.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Leptin is a hormone secreted by fat cells under normal conditions and acts in the brain to
      regulate energy usage and hormone levels. Women with HA who do not have regular periods have
      low leptin levels and may also have other hormone abnormalities as well as loss of bone
      density (osteopenia or osteoporosis). This study will evaluate how leptin (a fat cell hormone
      that normally circulates in the blood) affects bone density, menstrual periods, hormone
      levels, bone metabolism (how bone forms and turns over), immune function (how well the body
      can fight infection), metabolic rate (how many calories are used at rest), and overall sense
      of well-being and appetite in women with HA (i.e. no regular menstrual periods due to low
      levels of pituitary hormones that regulate estrogen production from the ovary). It will also
      investigate whether leptin replacement can be used as an adjunct to the current standard of
      care for HA patients, i.e. OCPs.

      Part A is a Randomized, placebo-controlled 36-week study. Part B is an Optional open-label
      52-week study. There will also be an optional Reward Sub-study, including healthy controls,
      designed to investigate leptin's relation to reward processing by collecting participants'
      brain and behavioral responses to images (e.g., pictures of food vs. non-food). Brain
      responses will be collected and will also be assessed via functional Magnetic Resonance
      Imaging (fMRI).

      Comparison: Part A = leptin-treated group to placebo-treated group and Part B optional sub
      study = leptin-treated group to health controls
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the Difference Between the Placebo and Leptin Treated Groups in the Change in Bone Mineral Content(BMC) at the Anteroposterior (AP) Spine From Baseline to 36 Weeks</measure>
    <time_frame>36 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Markers - Ctx and Sclerostin</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition BMI</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body BMD</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Fat</measure>
    <time_frame>36 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Body BMD</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lumbar BMD</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radial BMD</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hip BMD</measure>
    <time_frame>9months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Amenorrhea</condition>
  <arm_group>
    <arm_group_label>r-metHuLeptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>r-metHuLeptin administered subcutaneously.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Contraceptive Pills (OCPs)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PLACEBO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>r-metHuLeptin</intervention_name>
    <description>Starting dose: 0.08mg/kg once daily Subcutaneous injection.</description>
    <arm_group_label>r-metHuLeptin</arm_group_label>
    <other_name>metreleptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Contraceptive Pills (OCPs)</intervention_name>
    <description>Sprintec taken orally once daily.</description>
    <arm_group_label>r-metHuLeptin</arm_group_label>
    <arm_group_label>Oral Contraceptive Pills (OCPs)</arm_group_label>
    <other_name>OCPs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo (no active medication)</description>
    <arm_group_label>Oral Contraceptive Pills (OCPs)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for HA subjects

          -  Hypothalamic amenorrhea of at least 6 months duration with low or normal LH and FSH,
             e.g. due to strenuous exercise (running &gt;20 miles per week or equivalent) or low
             weight

          -  Can be secondary HA OR primary HA with some pubertal development and normal screening
             labs

          -  Age 18-35 years old

          -  Body weight within +/- 15% of ideal body weight and stable for 6 months (no change &gt; 5
             lbs)

          -  Baseline leptin &lt;5 ng/mL (except for the Cognitive Sub-Study Baseline visit where
             baseline leptin will be greater than 5ng/mL)

        Inclusion criteria for eumenorrheic controls for Reward Sub-study

          -  Normal menstrual cycles (between 25 and 35 days)

          -  Age 18-35

          -  Body weight within +/- 15% of ideal body weight and stable 6 months (no change &gt; 5
             lbs)

          -  Baseline leptin &gt;5 ng/mL

        Exclusion criteria:

          -  We will exclude subjects with:

          -  Significant medical history that may affect the concentrations of the hormones to
             studied or ability to participate in the study

          -  renal or hepatic disease (creatinine &gt; 1.4, AST/ALT &gt; 2x upper limit of normal)

          -  diagnosed diabetes mellitus

          -  myocardial ischemia

          -  malignancy (other than basal cell carcinoma of the skin or in situ carcinoma of the
             cervix)

          -  malabsorption

          -  alcoholism, drug abuse, or smoking

          -  active eating disorder

          -  depression or other psychiatric disease

          -  anemia (Hb10 gm/dL on 2 occasions)

          -  Conditions that are contraindicated for oral contraceptive use:

          -  Thrombophlebitis or thromboembolic disorders

          -  A past history of deep vein thrombophlebitis or thromboembolic disorders

          -  Cerebral vascular or coronary artery disease

          -  Known or suspected carcinoma of the breast

          -  Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia

          -  Undiagnosed abnormal genital bleeding

          -  Hepatic adenomas or carcinomas

          -  Cholestatic jaundice of pregnancy or jaundice with prior OCP use

          -  Other endocrine causes of amenorrhea, e.g.

          -  hyperprolactinemia

          -  hypothyroidism or hyperthyroidism

          -  Cushing's syndrome

          -  congenital adrenal hyperplasia (elevated 17 OH progesterone)

          -  polycystic ovarian syndrome (elevated androgens or LH/FSH ratio &gt;1.5)

          -  primary ovarian failure (elevated FSH)

          -  On medications known to affect the hormones to be measured such as

          -  glucocorticoids

          -  anti seizure medications

          -  thyroid hormones

          -  estrogen (must be off at least 3 months prior to participating in the study)

          -  A known history of anaphylaxis or anaphylactoid-like reactions, or a known
             hypersensitivity to E. Coli derived proteins

          -  Breast feeding, pregnant, or wanting to become pregnant during the next 6 months.

          -  We will screen for these conditions through a detailed history and systems review,
             physical examination, laboratory evaluation (as described above in Screening Methods),
             and EKG.

          -  In the Reward Sub-study subjects will be asked to fill out a standard BIDMC MRI safety
             screening form prior to entering the magnet.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos S Mantzoros, MD, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center, Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center General Clinical Research Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bidmc.org/Research/Departments/Medicine/Divisions/Endocrinology/Laboratories/MantzorosLab.aspx</url>
    <description>Click here for more information about the Mantzoros Research Group.</description>
  </link>
  <link>
    <url>http://www.bidmc.org/</url>
    <description>Click here for more information about Beth Israel Deaconess Medical Center.</description>
  </link>
  <reference>
    <citation>Welt CK, Chan JL, Bullen J, Murphy R, Smith P, DePaoli AM, Karalis A, Mantzoros CS. Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med. 2004 Sep 2;351(10):987-97.</citation>
    <PMID>15342807</PMID>
  </reference>
  <reference>
    <citation>Mantzoros CS, Magkos F, Brinkoetter M, Sienkiewicz E, Dardeno TA, Kim SY, Hamnvik OP, Koniaris A. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab. 2011 Oct;301(4):E567-84. doi: 10.1152/ajpendo.00315.2011. Epub 2011 Jul 26. Review.</citation>
    <PMID>21791620</PMID>
  </reference>
  <results_reference>
    <citation>Sienkiewicz E, Magkos F, Aronis KN, Brinkoetter M, Chamberland JP, Chou S, Arampatzi KM, Gao C, Koniaris A, Mantzoros CS. Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women. Metabolism. 2011 Sep;60(9):1211-21. doi: 10.1016/j.metabol.2011.05.016. Epub 2011 Jul 7.</citation>
    <PMID>21741057</PMID>
  </results_reference>
  <results_reference>
    <citation>Chou SH, Chamberland JP, Liu X, Matarese G, Gao C, Stefanakis R, Brinkoetter MT, Gong H, Arampatzi K, Mantzoros CS. Leptin is an effective treatment for hypothalamic amenorrhea. Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6585-90. doi: 10.1073/pnas.1015674108. Epub 2011 Apr 4.</citation>
    <PMID>21464293</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2005</study_first_submitted>
  <study_first_submitted_qc>August 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2005</study_first_posted>
  <results_first_submitted>December 24, 2015</results_first_submitted>
  <results_first_submitted_qc>April 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2017</results_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Christos Mantzoros</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>leptin</keyword>
  <keyword>hypothalamic amenorrhea</keyword>
  <keyword>exercise-induced amenorrhea</keyword>
  <keyword>neuroendocrine function</keyword>
  <keyword>bone metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amenorrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>r-metHuLeptin</title>
          <description>r-metHuLeptin administered subcutaneously.
r-metHuLeptin: Starting dose: 0.08mg/kg once daily Subcutaneous injection.
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.
Placebo: placebo (no active medication)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>r-metHuLeptin</title>
          <description>r-metHuLeptin administered subcutaneously.
r-metHuLeptin: Starting dose: 0.08mg/kg once daily Subcutaneous injection.
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.
Placebo: placebo (no active medication)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.6" spread="1.4"/>
                    <measurement group_id="B2" value="25.4" spread="1.2"/>
                    <measurement group_id="B3" value="26" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>the Difference Between the Placebo and Leptin Treated Groups in the Change in Bone Mineral Content(BMC) at the Anteroposterior (AP) Spine From Baseline to 36 Weeks</title>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>r-metHuLeptin</title>
            <description>r-metHuLeptin administered subcutaneously.
r-metHuLeptin: Starting dose: 0.08mg/kg once daily Subcutaneous injection.
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.
Placebo: placebo (no active medication)</description>
          </group>
        </group_list>
        <measure>
          <title>the Difference Between the Placebo and Leptin Treated Groups in the Change in Bone Mineral Content(BMC) at the Anteroposterior (AP) Spine From Baseline to 36 Weeks</title>
          <units>g</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0" lower_limit="43.4" upper_limit="58.2"/>
                    <measurement group_id="O2" value="58.2" lower_limit="55.2" upper_limit="61.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Markers - Ctx and Sclerostin</title>
        <time_frame>36 weeks</time_frame>
        <population>Only for subjects participating in both phase A and phase B (n=4), bone markers were assessed to see the change over 24 month period. All these patient got metreleptin treatment</population>
        <group_list>
          <group group_id="O1">
            <title>r-metHuLeptin</title>
            <description>r-metHuLeptin administered subcutaneously.
r-metHuLeptin: Starting dose: 0.08mg/kg once daily Subcutaneous injection.
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Markers - Ctx and Sclerostin</title>
          <population>Only for subjects participating in both phase A and phase B (n=4), bone markers were assessed to see the change over 24 month period. All these patient got metreleptin treatment</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CTX</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" lower_limit="0.39" upper_limit="0.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sclerostin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" lower_limit="0.07" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>p value reflects treatment of leptin for &quot;on-treatment&quot;, n=4</p_value_desc>
            <method>ANOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>0.60</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Composition BMI</title>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>r-metHuLeptin</title>
            <description>r-metHuLeptin administered subcutaneously.
r-metHuLeptin: Starting dose: 0.08mg/kg once daily Subcutaneous injection.
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.
Placebo: placebo (no active medication)</description>
          </group>
        </group_list>
        <measure>
          <title>Body Composition BMI</title>
          <units>BMI-kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" spread="0.6"/>
                    <measurement group_id="O2" value="21.1" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body BMD</title>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>r-metHuLeptin</title>
            <description>r-metHuLeptin administered subcutaneously.
r-metHuLeptin: Starting dose: 0.08mg/kg once daily Subcutaneous injection.
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.
Placebo: placebo (no active medication)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body BMD</title>
          <units>g/cm^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07" lower_limit="1.05" upper_limit="1.16"/>
                    <measurement group_id="O2" value="1.13" lower_limit="1.09" upper_limit="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Fat</title>
        <time_frame>36 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>r-metHuLeptin</title>
            <description>r-metHuLeptin administered subcutaneously.
r-metHuLeptin: Starting dose: 0.08mg/kg once daily Subcutaneous injection.
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.
Placebo: placebo (no active medication)</description>
          </group>
        </group_list>
        <measure>
          <title>Body Fat</title>
          <units>fat %</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" spread="1.4"/>
                    <measurement group_id="O2" value="20.8" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Body BMD</title>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>r-metHuLeptin</title>
            <description>r-metHuLeptin administered subcutaneously.
r-metHuLeptin: Starting dose: 0.08mg/kg once daily Subcutaneous injection.
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Oral Contraceptive Pills (OCPs)</title>
            <description>PLACEBO
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.
Placebo: placebo (no active medication)</description>
          </group>
        </group_list>
        <measure>
          <title>Total Body BMD</title>
          <units>g/cm2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="1.06" upper_limit="1.15"/>
                    <measurement group_id="O2" value="1.13" lower_limit="1.10" upper_limit="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lumbar BMD</title>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>r-metHuLeptin</title>
            <description>r-metHuLeptin administered subcutaneously.
r-metHuLeptin: Starting dose: 0.08mg/kg once daily Subcutaneous injection.
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.
Placebo: placebo (no active medication)</description>
          </group>
        </group_list>
        <measure>
          <title>Lumbar BMD</title>
          <units>g/cm2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" lower_limit="0.80" upper_limit="1.03"/>
                    <measurement group_id="O2" value="0.97" lower_limit="0.90" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Radial BMD</title>
        <time_frame>9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>r-metHuLeptin</title>
            <description>r-metHuLeptin administered subcutaneously.
r-metHuLeptin: Starting dose: 0.08mg/kg once daily Subcutaneous injection.
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.
Placebo: placebo (no active medication)</description>
          </group>
        </group_list>
        <measure>
          <title>Radial BMD</title>
          <units>g/cm2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" lower_limit="0.52" upper_limit="0.60"/>
                    <measurement group_id="O2" value="0.54" lower_limit="0.53" upper_limit="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hip BMD</title>
        <time_frame>9months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>r-metHuLeptin</title>
            <description>r-metHuLeptin administered subcutaneously.
r-metHuLeptin: Starting dose: 0.08mg/kg once daily Subcutaneous injection.
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.
Placebo: placebo (no active medication)</description>
          </group>
        </group_list>
        <measure>
          <title>Hip BMD</title>
          <units>g/cm2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0.80" upper_limit="1.03"/>
                    <measurement group_id="O2" value="0.88" lower_limit="0.80" upper_limit="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>11 participants started on the metreleptin arm , although only 7 finished the study. hence participants at risk are 11</desc>
      <group_list>
        <group group_id="E1">
          <title>r-metHuLeptin</title>
          <description>r-metHuLeptin administered subcutaneously.
r-metHuLeptin: Starting dose: 0.08mg/kg once daily Subcutaneous injection.
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo
Oral Contraceptive Pills (OCPs): Sprintec taken orally once daily.
Placebo: placebo (no active medication)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>local injection site reactions with erythematous rashes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Number of participants was small and, therefore, our observations need to be validated in studies with larger sample sizes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christos Mantzoros</name_or_title>
      <organization>BIDMC</organization>
      <phone>6176678630</phone>
      <email>cmantzor@bidmc.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

